Your browser doesn't support javascript.
loading
Immunogenicity of bivalent omicron (BA.1) booster vaccination after different priming regimens in health-care workers in the Netherlands (SWITCH ON): results from the direct boost group of an open-label, multicentre, randomised controlled trial.
Tan, Ngoc H; Geers, Daryl; Sablerolles, Roos S G; Rietdijk, Wim J R; Goorhuis, Abraham; Postma, Douwe F; Visser, Leo G; Bogers, Susanne; van Dijk, Laura L A; Gommers, Lennert; van Leeuwen, Leanne P M; Boerma, Annemarie; Nijhof, Sander H; van Dort, Karel A; Koopmans, Marion P G; Dalm, Virgil A S H; Lafeber, Melvin; Kootstra, Neeltje A; Huckriede, Anke L W; van Baarle, Debbie; Zaeck, Luca M; GeurtsvanKessel, Corine H; de Vries, Rory D; van der Kuy, P Hugo M.
Affiliation
  • Tan NH; Department of Hospital Pharmacy, Erasmus Medical Center, Rotterdam, Netherlands.
  • Geers D; Department of Viroscience, Erasmus Medical Center, Rotterdam, Netherlands.
  • Sablerolles RSG; Department of Hospital Pharmacy, Erasmus Medical Center, Rotterdam, Netherlands.
  • Rietdijk WJR; Department of Hospital Pharmacy, Erasmus Medical Center, Rotterdam, Netherlands.
  • Goorhuis A; Center of Tropical Medicine and Travel Medicine, Department of Infectious Diseases, Amsterdam University Medical Centers, Amsterdam, Netherlands; Infection and Immunity, Amsterdam Public Health, University of Amsterdam, Amsterdam, Netherlands.
  • Postma DF; Department of Internal Medicine and Infectious Diseases, University Medical Center Groningen, Groningen, Netherlands.
  • Visser LG; Department of Infectious Diseases, Leiden University Medical Center, Leiden, Netherlands.
  • Bogers S; Department of Viroscience, Erasmus Medical Center, Rotterdam, Netherlands.
  • van Dijk LLA; Department of Viroscience, Erasmus Medical Center, Rotterdam, Netherlands.
  • Gommers L; Department of Viroscience, Erasmus Medical Center, Rotterdam, Netherlands.
  • van Leeuwen LPM; Department of Viroscience, Erasmus Medical Center, Rotterdam, Netherlands.
  • Boerma A; Department of Medical Microbiology and Infection Prevention, University Medical Center Groningen, Groningen, Netherlands.
  • Nijhof SH; Department of Medical Microbiology and Infection Prevention, University Medical Center Groningen, Groningen, Netherlands.
  • van Dort KA; Department of Experimental Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands.
  • Koopmans MPG; Department of Viroscience, Erasmus Medical Center, Rotterdam, Netherlands.
  • Dalm VASH; Department of Internal Medicine, Division of Allergy and Clinical Immunology and Department of Immunology, Erasmus Medical Center, Rotterdam, Netherlands.
  • Lafeber M; Department of Internal Medicine, Erasmus Medical Center, Rotterdam, Netherlands.
  • Kootstra NA; Department of Experimental Immunology, Amsterdam University Medical Centers, Amsterdam, Netherlands.
  • Huckriede ALW; Department of Medical Microbiology and Infection Prevention, University Medical Center Groningen, Groningen, Netherlands.
  • van Baarle D; Department of Medical Microbiology and Infection Prevention, University Medical Center Groningen, Groningen, Netherlands; Center for Infectious Disease Control, National Institute for Public Health and the Environment, Bilthoven, Netherlands.
  • Zaeck LM; Department of Viroscience, Erasmus Medical Center, Rotterdam, Netherlands.
  • GeurtsvanKessel CH; Department of Viroscience, Erasmus Medical Center, Rotterdam, Netherlands.
  • de Vries RD; Department of Viroscience, Erasmus Medical Center, Rotterdam, Netherlands.
  • van der Kuy PHM; Department of Hospital Pharmacy, Erasmus Medical Center, Rotterdam, Netherlands. Electronic address: h.vanderkuy@erasmusmc.nl.
Lancet Infect Dis ; 23(8): 901-913, 2023 08.
Article in En | MEDLINE | ID: mdl-37088096
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Health context: 1_ASSA2030 / 2_ODS3 / 4_TD Database: MEDLINE Main subject: COVID-19 / Ad26COVS1 Type of study: Clinical_trials / Guideline Limits: Adult / Female / Humans / Male Country/Region as subject: Europa Language: En Journal: Lancet Infect Dis Year: 2023 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Health context: 1_ASSA2030 / 2_ODS3 / 4_TD Database: MEDLINE Main subject: COVID-19 / Ad26COVS1 Type of study: Clinical_trials / Guideline Limits: Adult / Female / Humans / Male Country/Region as subject: Europa Language: En Journal: Lancet Infect Dis Year: 2023 Document type: Article